2
Announcements
Trials
Browse
Landscape
Phase
Phase 4
1
Phase 3
1
Phase 2
1
Status
Completed
3
Sponsor Class
INDUSTRY
2
OTHER
1
Study Type
Interventional
3
Sponsor
Cancer Type
Endocrine
3
Breast
2
Conditions
Breast Neoplasms
48
Neoplasm Metastasis
11
Hereditary Sensory and Autonomic Neuropathies
7
Squamous Cell Carcinoma of Head and Neck
5
Recurrence
5
Ovarian Neoplasms
5
Neoplasms
5
Triple Negative Breast Neoplasms
3
Multiple Endocrine Neoplasia Type 1
3
Lymphangioma
3
Hyperglycemia
3
Head and Neck Neoplasms
3
Pancreatic Neoplasms
2
Melanoma
2
Lymphatic Abnormalities
2
Lymphangioma, Cystic
2
Head and Neck Squamous Cell Cancer
2
Endometrial Neoplasms
2
Colorectal Neoplasms
2
Advanced Breast Cancer
2
Vascular Malformations
1
Uveal Melanoma
1
Stomach Neoplasms Esophageal Neoplasms Metastatic Gastric Cancer Mutated PI3KCA Protein Overexpressed HER2 Protein
1
Stomach Neoplasms
1
Solid Tumor
1
Skin Diseases, Vascular
1
Sarcoma
1
Rectal Neoplasms
1
Prostatic Neoplasms
1
Pre-menopausal Breast Cancer
1
Interventions
Fulvestrant
5
Exercise
5
Eating
5
Standard of Care
3
Sodium Chloride
3
Diet
3
Alpelisib
3
ribociclib
2
gallium Ga 68 dotatate
2
exemestane
2
Vitamin D
2
Tamoxifen
2
Magnetic Resonance Spectroscopy
2
Letrozole
2
Ethanol
2
Blood Specimen Collection
2
Anastrozole
2
zopiclone
1
ziprasidone
1
veliparib
1
testosterone undecanoate
1
testosterone enanthate
1
pazopanib
1
mirabegron
1
methyl hydroxyethyl cellulose
1
lenvatinib
1
fluorocholine
1
evolocumab
1
dimethandrolone-undecanoate
1
cyclopropapyrroloindole
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
3 trials
Recent
Start date
Enrollment
Multiple Endocrine Neoplasia Type 1
×
Alpelisib
×
Clear all
NCT05631795
2026-04-07
ALPINIST
Novartis
Phase 4
Completed
40 enrolled
NCT04300790
2025-07-29
METALLICA
MedSIR
Phase 2
Completed
69 enrolled
NCT02437318
2025-02-13
SOLAR-1
Novartis
Phase 3
Completed
572 enrolled
22 charts
1 FDA